Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics nature.com/articles/s4140β¦
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer | BMC Cancer bmccancer.biomedcentral.cβ¦
PPARΞ± agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARΞ±/AMPK/AKT/FoxO1 pathway nature.com/articles/s4140β¦
Efficacy and dose of afatinib in patients with nonβsmall cell lung cancer after failure of prior gefitinib or erlotinib treatment onlinelibrary.wiley.com/dβ¦
Yi-Long Wu, MD, on Gefitinib Gaining Ground in EGFR-Mutant NSCLC β EGFR TKI proves mettle in adjuvant setting and in combo with another TKI or radiotherapy medpagetoday.com/asco/lunβ¦
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer japsonline.com/admin/php/β¦
Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.
